Effect of Morinda officinalis capsule on osteoporosis in ovariectomized rats

Abstract

AimTo explore the therapeutic effects of Morinda officinalis capsules (MOP) on osteoporosis in ovariectomized rats. MethodsSix-month-old female Sprague–Dawley rats were induced for postmenopausal osteoporosis (PMOP) by bilateral ovariectomy and divided into seven groups as follows: sham-operated group, ovariectomized (OVX) control group, OVX treated with xianlinggubao (XLGB) (270 mg·kg−1·d−1), OVX treated with alendronate sodium (ALN) (3 mg·kg−1·d−1), and OVX treated with Morinda officinalis capsule (MOP) of graded doses (90, 270 and 810 mg·kg−1·d−1) groups. Oral treatments were administered daily on the 4th week after ovariectomy and lasted for 12 weeks. The bone mineral density was evaluated by dual-energy X-ray absorptiometry. The tartrate-resistant acid phosphatase (TRAP), alkaline phosphatase (AKP), and osteocalcin (OC) levels in the serum and plasma were determined by standard colorimetric and enzyme immunoassays methods. Bone biomechanical properties and morphological parameters were analyzed by three-point bending test and histomorphometry respectively. ResultsMorinda officinalis capsules at all doses were able to significantly prevent the OVX-induced loss of bone mass due to diminishing serum AKP and TRAP levels while elevating OC level in the plasma. Morinda officinalis capsules also enhanced the bone strength and prevented the deterioration of trabecular microarchitecture. ConclusionMorinda officinalis capsules possess potent anti-osteoporotic activity in OVX rats which could be an effective treatment for postmenopausal osteoporosis.